



## Microbiome in Cancer: Role in Carcinogenesis and Impact in Therapeutic Strategies

Guest Editor:

### Dr. Rui Ferreira

1. i3S–Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
2. Ipatimup–Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal

Deadline for manuscript submissions:

**closed (31 January 2023)**

### Message from the Guest Editor

In recent years, due to the significant advances in NGS technologies, our knowledge on the vast collection of microorganisms that lives in close association with humans has increased. Several lines of evidence suggest that microbial imbalance is associated with the development of cancer. Fine examples of this link can be observed for tissues routinely exposed to microorganisms, namely, those in colon and stomach. On the other hand, compelling evidence now suggests that the microbiome can influence responses to anti-tumoral therapeutics. For example, the gut microbiome signatures of patients who respond to immunotherapy are associated with enhanced systemic immunity and increased intratumoral immune infiltration. Moreover, microbial communities within the tumour microenvironment can also contribute to the efficacy of other anti-cancer therapies and affect treatment-associated toxicity. Based on this, the microbiome has garnered interest as a cancer biomarker, but also as a target in the treatment of cancer. This Special Issue will focus on the impact of the microbiome on cancer development and on the emerging role of microbial communities in the success of anti-cancer therapy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)